The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help ...

Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...

The FDA cited issues with a manufacturing facility as the reason for the rejection. J&J is currently “working closely” with ...

Businessman and entrepreneur Mark Cuban recently discussed leadership with Leadership Lab columnist Michael Pietrack. The ...

In this deep dive BioSpace explores the opportunities and challenges presented by the FDA’s accelerated approval program.